NAD+ has a central function in linking cellular metabolism to major cell signaling and gene regulation pathways. Defects in NAD+ homeostasis underpin a wide range of diseases, including cancer, metabolic disorders, and aging.
Our research focussed on the discovery of novel approaches to NAD+ Replenishment for restablishing NAD+ Homeostasis is centered on 2 main areas; (1) increasing de novo NAD+ synthesis via the Kynurenine Pathway and (2) limiting NAD+ consumption via development of new PARP inhibitors.
Whilst the beneficial effects of NAD+ boosting are well established in mitochondrial fitness, metabolism, and lifespan, to date, no therapeutic enhancers of de novo NAD+ biosynthesis have been reported. TES Pharma has developed the first potent and selective inhibitors of the enzyme, α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), a critical enzyme in the biosynthesis of nicotinamide adenine dinucleotide (NAD+) from tryptophan, that directly augment NAD+ biosynthesis.
Slowing down or arresting premature ageing
Complementing this approach and capitalising on our long standing expertise in PARP modulators we are progressing our novel PARP inhibitors for application to orphan diseases where they would be of use in slowing down or arresting premature ageing, such as Cockayne Syndrome.